Literature DB >> 16515686

A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?

Roberto Cardarelli1, John C Licciardone, Lockwood G Taylor.   

Abstract

BACKGROUND: A major marketing technique used by pharmaceutical companies is direct-to-physician marketing. This form of marketing frequently employs promotional marketing brochures, based on clinical research, which may influence how a physician prescribes medicines. This study's objective was to investigate whether or not the information in promotional brochures presented to physicians by pharmaceutical representatives is accurate, consistent, and valid with respect to the actual studies upon which the promotional brochures are based.
METHODS: Physicians in five clinics were asked to consecutively collect pharmaceutical promotional brochures and to send them all to a centralized location. The brochures for any class of medication were collected on a continuous basis until 20 distinct promotional brochures were received by a central location. Once the brochure was received, the corresponding original study was obtained. Two blinded reviewers performed an evidence-based review of the article, comparing data that was printed on the brochure to what was found in the original study.
RESULTS: Among the 20 studies, 75% of the studies were found to be valid, 80% were funded by the pharmaceutical company, 60% of the studies and the corresponding brochures presented patient-oriented outcomes, and 40% were compared to another treatment regimen. Of the 19 brochures that presented the data as graphs, 4 brochures presented a relative risk reduction while only 1 brochure presented an absolute risk reduction. 15% of the promotional marketing brochures presented data that was different from what was in the original published study.
CONCLUSION: Given the present findings, physicians should be cautious about drawing conclusions regarding a medication based on the marketing brochures provided by pharmaceutical companies.

Entities:  

Mesh:

Year:  2006        PMID: 16515686      PMCID: PMC1450290          DOI: 10.1186/1471-2296-7-13

Source DB:  PubMed          Journal:  BMC Fam Pract        ISSN: 1471-2296            Impact factor:   2.497


  36 in total

1.  Physicians and the pharmaceutical industry: is a gift ever just a gift?

Authors:  A Wazana
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

2.  Influence of physician's education, drug information and medical-care settings on the quality of drugs prescribed.

Authors:  A Figueiras; F Caamaño; J J Gestal-Otero
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

3.  The uncertainty principle and industry-sponsored research.

Authors:  B Djulbegovic; M Lacevic; A Cantor; K K Fields; C L Bennett; J R Adams; N M Kuderer; G H Lyman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

Review 4.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

5.  Are sample medicines hurting the uninsured?

Authors:  John Zweifler; Susan Hughes; Sean Schafer; Bruno Garcia; Angela Grasser; Leticia Salazar
Journal:  J Am Board Fam Pract       Date:  2002 Sep-Oct

6.  Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension.

Authors:  K Tom Xu; Michael Moloney; Sidney Phillips
Journal:  Am J Manag Care       Date:  2003-08       Impact factor: 2.229

7.  All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving.

Authors:  Dana Katz; Arthur L Caplan; Jon F Merz
Journal:  Am J Bioeth       Date:  2003       Impact factor: 11.229

8.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

9.  Bias, prevalence and kappa.

Authors:  T Byrt; J Bishop; J B Carlin
Journal:  J Clin Epidemiol       Date:  1993-05       Impact factor: 6.437

10.  Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy.

Authors:  Lionel H Opie; Robert Schall
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

View more
  17 in total

1.  Information provided by generic and brand-name pharmaceutical manufacturers in response to a request.

Authors:  Fernando Fernandez-Llimos; Isabel Vazquez Gomez
Journal:  Pharm World Sci       Date:  2007-04-27

2.  Assessment of a Pharmaceutical Advertisement Analysis Module in a Drug Literature Evaluation Course.

Authors:  Mohamed Ezzat Khamis Amin; Youssef Fattouh
Journal:  Am J Pharm Educ       Date:  2017-08       Impact factor: 2.047

3.  Evaluation of rationality of promotional drug literature using World Health Organization guidelines.

Authors:  Smita N Mali; Sujata Dudhgaonkar; N P Bachewar
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

4.  Is availability of endoscopy changing initial management of vesicoureteral reflux?

Authors:  Caleb P Nelson; Hillary L Copp; Julie Lai; Christopher S Saigal
Journal:  J Urol       Date:  2009-07-22       Impact factor: 7.450

5.  Pharmaceutical company influence on nonsteroidal anti-inflammatory drug prescribing behaviors.

Authors:  Anand D Naik; Aaron L Woofter; Jessica M Skinner; Neena S Abraham
Journal:  Am J Manag Care       Date:  2009-04-01       Impact factor: 2.229

6.  Ethical issues in new drug prescribing.

Authors:  Lindsay W Cole; Jennifer C Kesselheim; Aaron S Kesselheim
Journal:  J Bioeth Inq       Date:  2011-12-15       Impact factor: 1.352

7.  Drug promotional literature distributed by pharmaceutical companies: Do they provide enough information to ascertain their validity?

Authors:  Deepak Saxena; Preeti Yadav; N D Kantharia
Journal:  J Pharmacol Pharmacother       Date:  2011-07

8.  Accuracy of drug advertisements in medical journals under new law regulating the marketing of pharmaceutical products in Switzerland.

Authors:  Macarena Gonzalez Santiago; Heiner C Bucher; Alain J Nordmann
Journal:  BMC Med Inform Decis Mak       Date:  2008-12-31       Impact factor: 2.796

9.  Overcoming obstacles to implementing a primary care research framework.

Authors:  Roberto Cardarelli; Margaret Seater; Elizabeth Palmarozzi
Journal:  Osteopath Med Prim Care       Date:  2007-02-01

Review 10.  Soft targets: nurses and the pharmaceutical industry.

Authors:  Annemarie Jutel; David B Menkes
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.